Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynogen Tries the SPAC Alternative

This article was originally published in Start Up

Executive Summary

Special Purpose Acquisition Companies--SPACs--are springing up in the wide spaces abandoned by IPOs-- and they look tempting for those biotechs who can't get to a Big Pharma deal without first raising a big slug of money. That's Dynogen's problem: no deal until it can show solid efficacy from its two lead compounds. With no IPO or big private financing likely, Dynogen turned to a SPAC, a public shell company created to find a Dynogen-like opportunity. But SPAC investors can extract a big price for their cooperation-particularly in the current risk-averse public market.

You may also be interested in...



Shell Game: Difficult Time For Reverse Mergers

Reverse mergers are an increasingly common fundraising strategy for biotech. But do they pay off?

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008

Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.

Best of the Blog: Start-Up April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel